Next Article in Journal
Four-Dimensional Magnetic Resonance Pulmonary Flow Imaging for Assessing Pulmonary Vasculopathy in Patients with Postcapillary Pulmonary Hypertension
Previous Article in Journal
Comorbid Attention-Deficit/Hyperactivity Disorder and Mood Disorder in a South African Sample of Substance Use Disorder Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 3
10.3390/jcm14030928
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Age-Related Outcomes in Patients Undergoing Coronary Angiography: In Which Subgroups Does Age Matter? Results from a Large-Scale Retrospective Registry

by
Lasse Kuhn
1,†,
Tobias Schupp
1,*,†,
Philipp Steinke
1,
Jonas Dudda
1,
Mohammad Abumayyaleh
1,
Kathrin Weidner
1,
Thomas Bertsch
2,
Jonas Rusnak
3,
Ibrahim Akin
1 and
Michael Behnes
1
1
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
2
Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital, Paracelsus Medical University, 90419 Nuremberg, Germany
3
Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2025, 14(3), 928; https://doi.org/10.3390/jcm14030928
Submission received: 31 December 2024 / Revised: 20 January 2025 / Accepted: 24 January 2025 / Published: 31 January 2025
(This article belongs to the Section Cardiology)
Browse Figures
Versions Notes

Abstract

:
Background: The study investigates age-related differences in the prevalence and extent of coronary artery disease (CAD), as well as long-term outcomes in a large cohort of unselected patients undergoing invasive coronary angiography (CA). The aging population, along with an increasing number of older and multi-morbid patients undergoing CA, poses challenges for healthcare systems. Despite this, studies investigating age-related differences in the long-term outcomes of unselected patients undergoing CA are limited. Methods: Consecutive patients undergoing invasive CA from 2016 to 2022 were included from one institution. The prognosis of patients undergoing CA stratified by pre-specified age groups (i.e., 40–<60, 60–<80 and ≥80 years) was investigated with regard to the primary endpoint of rehospitalization for heart failure (HF), as well as the risks of acute myocardial infarction (AMI) and coronary revascularization at 36 months. Results: From 2016 to 2022, 7520 patients undergoing CA were included with a median age of 70 years (mean: 69 years). The prevalence of CAD (61.9% vs. 71.8% vs. 77.3%; p = 0.001), as well as the prevalence of three-vessel CAD (21.0% vs. 31.5% vs. 36.1%) increased with age. At 36 months, patients ≥ 80 years of age had the highest rates of rehospitalization for HF, followed by patients 60–<80 years and patients 40–<60 years (28.4% vs. 23.2% vs. 14.0%; p = 0.001). Consequently, compared to younger patients (i.e., 40–<60 years of age), those ≥80 years of age exhibited the highest risk of HF-related rehospitalization (≥ 80 years: HR = 2.205; 95% CI 1.884–2.579; p = 0.001), followed by those 60–< 80 years (HR = 1.765; 95% CI 1.536–2.029; p = 0.001). The increased risk of rehospitalization for HF at 36 months was still observed after multivariable adjustment (i.e., ≥80 years: HR = 1.265; 95% CI 1.049–1.524; p = 0.014; 60–<80 years: HR = 1.339; 95% CI 1.145–1.565; p = 0.001) and was specifically evident in patients with left ventricular ejection fraction ≥ 35% and in patients without evidence of CAD/single-vessel CAD. In contrast, the rates of AMI and coronary revascularization at 36 months did not differ significantly among different age groups. Conclusions: Advanced age is an independent predictor of rehospitalization for HF in patients undergoing CA, but not AMI and revascularization during long-term follow-up. This highlights the importance of optimizing diagnostic and therapeutic strategies for HF, particularly in older patients undergoing CA.

1. Introduction

Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality worldwide, with an increasing prevalence in older patients [1]. According to estimates from the United Nations, the global prevalence of people aged 65 or older will rise from 10% in 2022 to 16% in 2050 [2]. Therefore, an increase in the number of older patients undergoing coronary angiography (CA) can be expected. Due to age-related changes in organ function and morphology, as well as a higher burden of cardiac and non-cardiac comorbidities associated with age, the diagnosis and treatment of CAD in older people poses significant challenges for healthcare systems. Specifically, elderly patients have often been excluded from prior studies focusing on revascularization strategies. Because of this, data focusing on invasive strategies in this population remains limited [3].
The rupture of atherosclerotic plaques plays a major role in the pathogenesis of CAD, myocardial infarction (MI), and heart failure (HF) [4,5]. Because atherosclerotic plaques develop over an extended period of time, the burden of atherosclerosis increases with age. This is further aggravated by the increasing prevalence of important cardiovascular risk factors among older patients [6,7,8]. It has been shown that CAD mortality increases by a factor of 2.3 to 4.5 per decade of life while also being influenced by sex and the region of observation [9]. Previous studies have suggested that patients of different age groups possess significantly differing risk profiles, implying the need for specific and risk-profile-adjusted treatment strategies [8,10]. However, prior studies often either solely include patients with acute coronary syndrome (ACS) or explicitly exclude older patients [11,12,13,14]. Detailed data regarding age-related differences in the diagnosis and treatment of CAD is limited.
This study aims to investigate the relationship between age and both the presence and extent of CAD, as well as long-term outcomes in a large cohort of unselected patients undergoing invasive CA. Furthermore, the prognostic impact of age was stratified by the indication of CA.

2. Materials and Methods

2.1. Study Patients, Design, and Data Collection

For the present study, all consecutive patients undergoing CA at the University Medical Centre Mannheim (UMM), Germany, from January 2016 to August 2022 were included. Patients were identified using Operation and Procedure Classification (OPS) codes. The local electronic hospital information system (SAP®, Walldorf, Germany) was used to retrospectively document all relevant clinical data related to the index event, including symptoms and diagnosis on admission, prior medical history, and angiographic findings and interventions, as well as medication on discharge. Patients who underwent recurrent CA were only included once.
The UMM has a general emergency department to cater to emergency traumatic, surgical, neurological, and cardiovascular conditions. The cardiology department offers a 24/7 h catheterization laboratory, an electrophysiologic laboratory, a hybrid operating room, and telemetry units. Furthermore, the UMM is a part of an established network of clinics to which patients are sent who are in need of cardiac surgery, such as for coronary artery bypass grafts (CABGs).

2.2. Inclusion and Exclusion Criteria

For the present study, all consecutive patients ≥ 40 years of age undergoing invasive CA at our institution were included. CAs were performed by interventional cardiologists in accordance with current European guidelines [15]. CA operators were blinded to the final study analyses. For the present study, all source data of coronary angiographic examinations (imaging files) and reports were reassessed post hoc by two independent cardiologists. For the present study, risk stratification was performed comparing patients 40–<60 years, 60–<80 years, and ≥80 years. Patients < 40 years were excluded from the analysis due to their small number relative to the overall study cohort (171 out of 7691). No further exclusion criteria were applied.

2.3. Study Endpoints

The primary endpoint was rehospitalization for heart failure (HF) at 36 months. Secondary endpoints comprised the risk of acute myocardial infarction (AMI) and coronary revascularization at 36 months, as well as in-hospital all-cause mortality related to index hospitalization. All endpoints were defined using International Classification of Diseases (ICD) codes at the University Medical Centre Mannheim (UMM), Germany.

2.4. Statistical Methods

Quantitative data was presented as mean ± standard error of mean (SEM), median, and interquartile range (IQR), and ranges depending on the distribution of the data. They were compared using the Student’s t-test for normally distributed data or the Mann–Whitney U test for nonparametric data. Deviations from a Gaussian distribution were tested by the Kolmogorov–Smirnov test. Qualitative data was presented as absolute and relative frequencies and were compared using the Chi-square test or the Fisher’s exact test, where appropriate. Kaplan–Meier analyses investigating the risk of HF-related rehospitalization, coronary revascularization, and AMI were performed, including patients discharged alive. Univariable hazard ratios (HRs) were given, together with 95% confidence intervals.
The prognostic impact of age was thereafter investigated within multivariable Cox regression models. Multivariable Cox regression analyses were performed within the entire study cohort and also in pre-specified subgroups stratified by the presence of angina, (non-)ST segment elevation myocardial infarction ((N)STEMI), and decompensated HF at index hospitalization, multivessel CAD, and left ventricular ejection fraction (LVEF). Multivariable Cox regression analyses were visualized using forest plots. Multivariable Cox regression analyses within the entire study cohort were also performed, including age as a continuous variable (i.e., per 1-year increase).
The results of all statistical tests were considered significant for p ≤ 0.05. SPSS (Version 25 IBM, Armonk, NY, USA) was used for statistics.

3. Results

3.1. Study Population

From January 2016 to August 2022, 7520 patients undergoing CA at the catheterization unit of the University Medical Centre Mannheim were included in the present study. Patients’ mean age was 69 years (median: 70 years; IQR 60–79 years). Baseline characteristics and comorbidities on admission are shown in Table 1. The proportion of male patients (40–<60 years of age: 75.1% vs. 60–<80 years of age: 63.3% vs. ≥80 years of age: 55.8%; p = 0.001) as well as the rates of hyperlipidemia (44.1% vs. 33.7% vs. 29.1%; p = 0.001) decreased with age. In contrast, the rates of arterial hypertension increased in older patients (81.4% vs. 87.0% vs. 87.5%; p = 0.001). During index hospitalization, the highest rates of concomitant NSTEMI were found in patients aged ≥80 years, followed by patients aged 60–<80 and 40–<60 years (21.0% vs. 17.8% vs. 16.9%; p = 0.005). In contrast, unstable angina (21.9% vs. 25.5% vs. 32.1%; p = 0.001) and STEMI (7.9% vs. 10.0% vs. 18.3%; p = 0.001) were less frequently found in older patients.
Furthermore, the rates of moderately (i.e., 35–44%) (10.1% vs. 14.5% vs. 18.4%; p = 0.001) and severely reduced LVEF (i.e., <35%) (12.2% vs. 16.0% vs. 16.0%; p = 0.001) increased with age.
Angiographic findings, as well as clinical outcomes, are presented in Table 2. Patients aged ≥ 80 years exhibited the highest prevalence of CAD, followed by patients aged 60–<80 years and 40–<60 years (77.3% vs. 71.8% vs. 61.9%; p = 0.001), as well as the highest rate of two-vessel (22.4% vs. 20.9% vs. 19.1%; p = 0.001) and three-vessel disease (36.1% vs. 31.5% vs. 21.0%; p = 0.001).
Figure 1 shows significantly higher CAD prevalences in older patients within the entire study cohort when stratifying patient age into 10-year age increments: 51.4% in patients aged 40–<50 years compared to 81.6% in patients aged ≥ 90 years (p = 0.001). The prevalence of three-vessel disease rises from 14.3% to 41.4% when comparing the same age groups (p = 0.001).
This trend was also seen in different patient subgroups. In patients with LVEF ≥ 35%, the rates of CAD and three-vessel disease rise from 51.1% to 80.3% and from 14.0% to 36.4%, respectively (p = 0.001) (Figure 2E). In patients with LVEF < 35%, CAD prevalence rises from 51.9% to 84.6%, and three-vessel CAD prevalence rises from 15.4% to 46.2% (p = 0.001) (Figure 2F). A significant age-related increase in the prevalence of CAD and three-vessel disease was also observed in patients presenting with unstable angina (p = 0.001), STEMI (p = 0.001), NSTEMI (p = 0.001), and decompensated HF at index hospitalization (p = 0.001) (Figure 2A–D).
However, no significant age-related differences in the need for PCI were observed when comparing patients aged 40–<60, 60–<80, and ≥80 years (43.1–43.7%; p = 0.908) (Table 2).

3.2. Prognostic Impact of Age in Patients Undergoing CA

The primary endpoint of this study, rehospitalization for HF at 36 months, occurred in 14.0% of patients 40–<60 years of age, in 23.2% of patients 60–<80 years of age, and in 28.4% of patients ≥ 80 years of age (Figure 3). Compared with patients 40–<60 years of age, patients 60–<80 years of age (HR = 1.765; 95% CI: 1.536–2.029; p = 0.001) and ≥80 years of age (HR = 2.205; 95% CI: 1.884–2.579; p = 0.001) had a higher risk of rehospitalization for HF at 36 months (Figure 3).
Additionally, the risk of in-hospital all-cause mortality increased with age (3.8% vs. 7.1% vs. 9.7%; p = 0.001) (Table 2). However, no significant differences in the risk of coronary revascularization (8.1% vs. 9.0% vs. 7.2%; p = 0.089) and AMI (7.4% vs. 7.9% vs 7.2%; p = 0.654) at 36 months were observed among the three age groups (Figure 3).

3.3. Multivariable Cox Regression Analyses

After multivariable adjustment, advanced age was independently associated with a higher risk of rehospitalization for HF (i.e., 60–<80 years: HR = 1.339; 95% CI 1.145–1.565; p = 0.001; ≥80 years: HR = 1.265; 95% CI 1.049–1.524; p = 0.014) (Figure 4). Additionally, the presence of diabetes mellitus (HR = 1.226; 95% CI 1.096–1.372; p = 0.001), prior CAD (HR = 1.550; 95% CI 1.325–1.813; p = 0.001), prior CABG (HR = 1.236; 95% CI 1.029–1.485; p = 0.024), atrial fibrillation (HR = 1.235; 95% CI 1.101–1.385; p = 0.001), acute decompensated HF during index hospitalization (HR = 1.464; 95% CI 1.284–1.669; p = 0.001), and LVEF < 35% (HR = 1.614; 95% CI 1.538–1.694; p = 0.001) were associated with a higher risk of rehospitalization for HF at 36 months (Figure 4). However, a higher glomerular filtration rate (eGFR) (HR = 0.995; 95% CI 0.993–0.998; p = 0.001; per 1 mL/min increase) and higher hemoglobin levels (HR = 0.947; 95% CI 0.920–0.974; p = 0.001; per 1 g/dL increase) were associated with a lower risk of HF-related rehospitalization (Figure 4).
Even when included as a continuous variable, advanced age was still associated with a higher risk of HF-related rehospitalization at 36 months (HR = 1.010, 95% CI 1.004–1.015, p = 0.001, per 1-year increase).
Within the following subgroup analyses, advanced age was associated with a significantly higher risk of HF-related rehospitalization at 36 months in patients with no evidence of CAD or single-vessel disease (60–<80 years: HR = 1.310, 95% CI 1.045–1.644; p = 0.019; ≥80 years: HR = 1.445, 95% CI 1.093–1.911; p = 0.010) and in patients with a LVEF ≥ 35% (60–<80 years: HR = 1.469, 95% CI 1.211–1.783; p = 0.001; ≥80 years: HR = 1.591; 95% CI 1.270–1.992; p = 0.001) (Figure 5).

4. Discussion

The aim of the present study was to investigate age-related differences in the presence and extent of CAD, as well as long-term outcomes in a large cohort of unselected patients undergoing invasive CA from 2016 to 2022. The main findings of our study can be summarized as follows: the prevalence of CAD, particularly multivessel CAD, increased with age and was highest in patients ≥80 years of age. Patients with ≥80 years of age had the highest risk of rehospitalization for HF at 36 months, as well as the highest risk of in-hospital all-cause mortality. This was especially evident in patients without evidence of CAD or single-vessel disease and in patients with LVEF ≥ 35%. However, the rates of AMI and coronary revascularization did not differ among different age groups during 36 months of follow-up.
The growth of atherosclerotic plaques, which is the main driving force in the development and progression of CAD, accelerates with increasing age [16]. Older patients typically present with a higher plaque volume and greater plaque calcification than younger patients [7,17,18]. While young patients undergoing CA typically present with higher rates of obesity and hyperlipidemia, the prevalences of diabetes mellitus and hypertension increase with advancing age [13,19,20,21]. A similar pattern in the distribution of the above-mentioned risk factors was observed in the present study. Accordingly, age represents an important prognostic factor in the development and progression of many cardiovascular diseases. This applies, in particular, to the development of HF, which, given recent and ongoing demographic changes, represents an ever-increasing global health problem [1]. In older patients, a reduction in cardiac reserve is often observed. This is caused by various age-related processes, such as decreased sensitivity to β-adrenergic stimulation, reduced compliance of blood vessels and cardiac tissue, and impaired energy metabolism of the myocardium [22,23].
The main causes of HF are arterial hypertension, CAD, and valvular heart disease, all of which are more prevalent in older patients [22]. Arterial hypertension leads to a higher afterload, concentric left ventricular hypertrophy and may ultimately lead to diastolic dysfunction and HF with preserved ejection fraction (HFpEF) [24,25]. Consistent with the increasing prevalence of hypertension with age, the incidence of HFpEF also increases with age, while HF with reduced ejection fraction (HFrEF) tends to occur more frequently in younger patients [26,27,28]. Aortic valve stenosis (AS) is another pathology that facilitates the development of HF, particularly when it is accompanied by mitral regurgitation (MR) or CAD. Because AS can contribute to the development of MR and both AS and CAD share common pathophysiological mechanisms, the coexistence of these three conditions is frequently observed [29,30]. The present study found that the percentage of concomitant valvular heart disease in patients undergoing CA substantially increases with age, affecting nearly one-third of patients ≥ 80 years of age. Due to a higher burden of the aforementioned comorbidities, as well as improved survival rates after AMI in older patients and a consequent higher number of older patients possibly developing HF in the years following a myocardial infarction, the overall prevalence and mortality of HF increase significantly with age [22,31,32,33].
Furthermore, older patients undergoing CA present more frequently with NSTEMI and multi-vessel disease, while younger patients are more likely to present with STEMI and single-vessel disease [13,14,19,20,21]. Advanced age is a well-known independent predictor of increased short-term and long-term mortality in patients undergoing CA [14,20,34,35]. However, no significant age-related differences with regard to the risk of reinfarction were observed in previous studies [34,35]. This is consistent with our findings. While we found no significant differences in the risk of reinfarction or revascularization between age groups, we identified a significant age-dependent difference in the risk of rehospitalization for HF in patients undergoing CA.
Prior studies examining the outcomes of patients with suspected CAD predominantly included patients experiencing acute coronary syndrome (ACS) or AMI [13,14,34,35]. Data was commonly provided for the rates of HF upon admission or the risk for the development of in-hospital HF, but not for the long-term risk of developing HF after AMI [20,34,36].
As mentioned above, CAD is one of the leading causes of the development of HF. Conversely, HF is also a relatively common comorbidity in patients admitted for CA [37]. Furthermore, HF has been identified as an independent predictor of increased mortality in ACS patients [20,37]. Steg et al. found that the presence of HF on admission has the highest impact on mortality in patients <55 years of age compared to older patients [37]. Nevertheless, older patients undergoing CA are significantly more likely to present with HF on admission or to develop symptoms of HF during index hospitalization [20,34,36,38]. Finally, it has been shown that older patients are also at higher risk of developing HF in the years after receiving CA [38,39,40]. This is in line with our findings that patients aged 60–<80 years or ≥80 years are at higher risk of developing HF compared to patients aged 40–<60 years.
However, an increasing burden of comorbidities, as well as age-related remodeling processes and reduced cardiac reserve, contribute to an increased risk of HF-related rehospitalization after CA in older patients. In our study, this effect was especially seen in patients with no evidence of CAD or single-vessel disease and in patients with an LVEF ≥ 35%. Advanced age has been associated with an increased risk of long-term mortality both in patients with HFrEF [41,42] and HFpEF [43,44]. It has also been reported that the prognosis of older patients with HFrEF is worse than that of older patients with HFpEF [45,46]. Knowing this, patients with a higher risk, i.e., patients with severely reduced LVEF and/or multivessel disease, may die before being hospitalized for HF, which may partly explain the low impact of age on the risk of HF-related rehospitalization in these subgroups in the present study.
In light of ongoing demographic changes, optimizing the diagnosis and treatment of CAD and HF, as well as of cardiac and non-cardiac comorbidities, is becoming increasingly important, especially in older patients. Considering all of the above-mentioned phenomena and trends, patients ≥ 60 years of age should be regularly monitored following CA, even in patients with no evidence of obstructive CAD or single-vessel CAD, as well as in patients with LVEF ≥ 35%.

Study Limitations

The study has several limitations. Firstly, all data, including follow-up data, were sourced solely from hospital records. Additionally, patients’ prior medical histories were assessed using OPS codes, which might lead to lower documented event rates of pre-existing illnesses. A major limitation of this study was the unavailability of data regarding long-term all-cause mortality beyond index hospitalization—especially considering the risk interaction between rehospitalization and death. Moreover, the design of this study was retrospective and single-center. As a result, despite multivariable Cox regression analyses, results may be influenced by measured and unmeasured confounding factors, including undiagnosed comorbidities, medication adherence, or lifestyle differences between the age groups. Additionally, despite the consecutive inclusion of patients, biases may arise from the selection of patients undergoing CA, as those with more severe or symptomatic CAD may have been preferentially selected. Another limitation was the fact that all endpoints were assessed at our institution only. Because of this, the results may not be generalizable to broader populations in different countries outside of Germany.

5. Conclusions

Higher age represents an independent predictor of rehospitalization for HF at 36 months in patients undergoing CA, particularly among those without evidence of CAD or single-vessel disease, and an LVEF ≥ 35%. In contrast, age did not predict the risk of AMI and coronary revascularization during long-term follow-up.

Author Contributions

Conceptualization, T.S., I.A. and M.B.; methodology, L.K., T.S. and P.S.; software, L.K., J.D. and J.R.; validation, T.B., K.W., T.S., M.A. and M.B.; formal analysis, L.K., T.S. and P.S.; investigation, L.K., T.S. and M.B.; resources, T.S., M.B. and K.W.; data curation, T.S. and K.W.; writing—original draft preparation, L.K.; writing—review and editing, T.S. and I.A.; visualization, T.S. and M.B.; supervision, T.S., M.A., I.A. and M.B.; project administration, T.S., M.B. and I.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee II of the Medical Faculty Mannheim (approval code: 2022-829) (19 May 2022).

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Alonso, A.; Beaton, A.Z.; Bittencourt, M.S.; Boehme, A.K.; Buxton, A.E.; Carson, A.P.; Commodore-Mensah, Y.; et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation 2022, 145, e153–e639. [Google Scholar] [CrossRef] [PubMed]
  2. Department of Economic and Social Affairs, Population Division, United Nations. World Population Prospects 2022: Ten Key Messages; United Nations: New York, NY, USA, 2022. [Google Scholar]
  3. Biscaglia, S.; Guiducci, V.; Escaned, J.; Moreno, R.; Lanzilotti, V.; Santarelli, A.; Cerrato, E.; Sacchetta, G.; Jurado-Roman, A.; Menozzi, A.; et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N. Engl. J. Med. 2023, 389, 889–898. [Google Scholar] [CrossRef] [PubMed]
  4. Scott, J. Pathophysiology and biochemistry of cardiovascular disease. Curr. Opin. Genet. Dev. 2004, 14, 271–279. [Google Scholar] [CrossRef] [PubMed]
  5. Bentzon, J.F.; Otsuka, F.; Virmani, R.; Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 2014, 114, 1852–1866. [Google Scholar] [CrossRef]
  6. Kannel, W.B. Coronary heart disease risk factors in the elderly. Am. J. Geriatr. Cardiol. 2002, 11, 101–107. [Google Scholar] [CrossRef]
  7. Kuller, L.; Borhani, N.; Furberg, C.; Gardin, J.; Manolio, T.; O’Leary, D.; Psaty, B.; Robbins, J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am. J. Epidemiol. 1994, 139, 1164–1179. [Google Scholar] [CrossRef]
  8. Badran, H.M.; Elnoamany, M.F.; Khalil, T.S.; Eldin, M.M. Age-related alteration of risk profile, inflammatory response, and angiographic findings in patients with acute coronary syndrome. Clin. Med. Cardiol. 2009, 3, 15–28. [Google Scholar] [CrossRef]
  9. Nowbar, A.N.; Howard, J.P.; Finegold, J.A.; Asaria, P.; Francis, D.P. 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: Statistics from World Health Organisation and United Nations. Int. J. Cardiol. 2014, 174, 293–298. [Google Scholar] [CrossRef]
  10. Siddique, M.A.; Shrestha, M.P.; Salman, M.; Haque, K.S.; Ahmed, M.K.; Sultan, M.A.U.; Hoque, M.H.; Zaman, S.M. Age-related differences of risk profile and angiographic findings in patients with coronary heart disease. Bangabandhu Sheikh Mujib Med. Univ. J. 2010, 3, 13–17. [Google Scholar] [CrossRef]
  11. Rich, M.W.; Chyun, D.A.; Skolnick, A.H.; Alexander, K.P.; Forman, D.E.; Kitzman, D.W.; Maurer, M.S.; McClurken, J.B.; Resnick, B.M.; Shen, W.K.; et al. Knowledge Gaps in Cardiovascular Care of Older Adults: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary. J. Am. Geriatr. Soc. 2016, 64, 2185–2192. [Google Scholar] [CrossRef]
  12. Lee, P.Y.; Alexander, K.P.; Hammill, B.G.; Pasquali, S.K.; Peterson, E.D. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001, 286, 708–713. [Google Scholar] [CrossRef] [PubMed]
  13. Stahli, B.E.; Wischnewsky, M.B.; Jakob, P.; Klingenberg, R.; Obeid, S.; Heg, D.; Raber, L.; Windecker, S.; Mach, F.; Gencer, B.; et al. Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. Catheter. Cardiovasc. Interv. 2019, 93, 16–24. [Google Scholar] [CrossRef] [PubMed]
  14. Kala, P.; Kanovsky, J.; Rokyta, R.; Smid, M.; Pospisil, J.; Knot, J.; Rohac, F.; Poloczek, M.; Ondrus, T.; Holicka, M.; et al. Age-related treatment strategy and long-term outcome in acute myocardial infarction patients in the PCI era. BMC Cardiovasc. Disord. 2012, 12, 31. [Google Scholar] [CrossRef] [PubMed]
  15. Byrne, R.A.; Rossello, X.; Coughlan, J.J.; Barbato, E.; Berry, C.; Chieffo, A.; Claeys, M.J.; Dan, G.A.; Dweck, M.R.; Galbraith, M.; et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J. Acute Cardiovasc. Care 2024, 13, 55–161. [Google Scholar] [CrossRef]
  16. Kim, M.; Lee, S.P.; Kwak, S.; Yang, S.; Kim, Y.J.; Andreini, D.; Al-Mallah, M.H.; Budoff, M.J.; Cademartiri, F.; Chinnaiyan, K.; et al. Impact of age on coronary artery plaque progression and clinical outcome: A PARADIGM substudy. J. Cardiovasc. Comput. Tomogr. 2021, 15, 232–239. [Google Scholar] [CrossRef]
  17. Jonas, R.; Earls, J.; Marques, H.; Chang, H.J.; Choi, J.H.; Doh, J.H.; Her, A.Y.; Koo, B.K.; Nam, C.W.; Park, H.B.; et al. Relationship of age, atherosclerosis and angiographic stenosis using artificial intelligence. Open Heart 2021, 8, e001832. [Google Scholar] [CrossRef]
  18. Wong, M.Y.Z.; Yap, J.; Huang, W.; Tan, S.Y.; Yeo, K.K. Impact of Age and Sex on Subclinical Coronary Atherosclerosis in a Healthy Asian Population. JACC Asia 2021, 1, 93–102. [Google Scholar] [CrossRef]
  19. Yang, Y.L.; Chen, S.C.; Wu, C.H.; Huang, S.S.; Leong Chan, W.; Lin, S.J.; Chou, C.Y.; Chen, J.W.; Pan, J.P.; Charng, M.J.; et al. Sex and age differences of major cardiovascular events in patients after percutaneous coronary intervention. J. Chin. Med. Assoc. 2023, 86, 1046–1052. [Google Scholar] [CrossRef]
  20. Noaman, S.; Dinh, D.; Reid, C.M.; Brennan, A.L.; Clark, D.; Shaw, J.; Freeman, M.; Sebastian, M.; Oqueli, E.; Ajani, A.; et al. Comparison of Outcomes of Coronary Artery Disease Treated by Percutaneous Coronary Intervention in 3 Different Age Groups (<45, 46–65, and >65 Years). Am. J. Cardiol. 2021, 152, 19–26. [Google Scholar] [CrossRef]
  21. Flather, M.; Rhee, J.W.; Boothroyd, D.B.; Boersma, E.; Brooks, M.M.; Carrie, D.; Clayton, T.C.; Danchin, N.; Hamm, C.W.; Hueb, W.A.; et al. The effect of age on outcomes of coronary artery bypass surgery compared with balloon angioplasty or bare-metal stent implantation among patients with multivessel coronary disease. A collaborative analysis of individual patient data from 10 randomized trials. J. Am. Coll. Cardiol. 2012, 60, 2150–2157. [Google Scholar] [CrossRef]
  22. Rich, M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J. Am. Geriatr. Soc. 1997, 45, 968–974. [Google Scholar] [CrossRef] [PubMed]
  23. Wei, J.Y. Age and the cardiovascular system. N. Engl. J. Med. 1992, 327, 1735–1739. [Google Scholar] [CrossRef] [PubMed]
  24. Messerli, F.H. Cardiovascular effects of obesity and hypertension. Lancet 1982, 1, 1165–1168. [Google Scholar] [CrossRef] [PubMed]
  25. Messerli, F.H.; Rimoldi, S.F.; Bangalore, S. The Transition from Hypertension to Heart Failure: Contemporary Update. JACC Heart Fail. 2017, 5, 543–551. [Google Scholar] [CrossRef]
  26. Chen, X.; Savarese, G.; Dahlstrom, U.; Lund, L.H.; Fu, M. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clin. Res. Cardiol. 2019, 108, 1394–1405. [Google Scholar] [CrossRef]
  27. Lam, C.S.P.; Pina, I.L.; Zheng, Y.; Bonderman, D.; Pouleur, A.C.; Saldarriaga, C.; Pieske, B.; Blaustein, R.O.; Nkulikiyinka, R.; Westerhout, C.M.; et al. Age, Sex, and Outcomes in Heart Failure with Reduced EF: Insights from the VICTORIA Trial. JACC Heart Fail. 2023, 11, 1246–1257. [Google Scholar] [CrossRef]
  28. Tromp, J.; Paniagua, S.M.A.; Lau, E.S.; Allen, N.B.; Blaha, M.J.; Gansevoort, R.T.; Hillege, H.L.; Lee, D.E.; Levy, D.; Vasan, R.S.; et al. Age dependent associations of risk factors with heart failure: Pooled population based cohort study. BMJ 2021, 372, n461. [Google Scholar] [CrossRef]
  29. Kamperidis, V.; Delgado, V.; van Mieghem, N.M.; Kappetein, A.P.; Leon, M.B.; Bax, J.J. Diagnosis and management of aortic valve stenosis in patients with heart failure. Eur. J. Heart Fail. 2016, 18, 469–481. [Google Scholar] [CrossRef]
  30. Abdul-Rahman, T.; Lizano-Jubert, I.; Garg, N.; Talukder, S.; Lopez, P.P.; Awuah, W.A.; Shah, R.; Chambergo, D.; Cantu-Herrera, E.; Farooqi, M.; et al. The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications. Prog. Cardiovasc. Dis. 2023, 79, 89–99. [Google Scholar] [CrossRef]
  31. Lloyd-Jones, D.M.; Larson, M.G.; Leip, E.P.; Beiser, A.; D’Agostino, R.B.; Kannel, W.B.; Murabito, J.M.; Vasan, R.S.; Benjamin, E.J.; Levy, D.; et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002, 106, 3068–3072. [Google Scholar] [CrossRef]
  32. Ho, K.K.; Pinsky, J.L.; Kannel, W.B.; Levy, D. The epidemiology of heart failure: The Framingham Study. J. Am. Coll. Cardiol. 1993, 22, 6A–13A. [Google Scholar] [CrossRef] [PubMed]
  33. Reinhardt, M.; Schupp, T.; Behnes, M.; Lau, F.; Schmitt, A.; Abel, N.; Akin, M.; Rusnak, J.; Akin, I.; Weidner, K. Age-Related Outcomes in Heart Failure with Mildly Reduced Ejection Fraction. J. Clin. Med. 2024, 13, 5151. [Google Scholar] [CrossRef] [PubMed]
  34. DeGeare, V.S.; Stone, G.W.; Grines, L.; Brodie, B.R.; Cox, D.A.; Garcia, E.; Wharton, T.P.; Boura, J.A.; O’Neill, W.W.; Grines, C.L. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am. J. Cardiol. 2000, 86, 30–34. [Google Scholar] [CrossRef] [PubMed]
  35. Zimmerman, F.H.; Cameron, A.; Fisher, L.D.; Ng, G. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J. Am. Coll. Cardiol. 1995, 26, 654–661. [Google Scholar] [CrossRef]
  36. Singh, M.; Mathew, V.; Garratt, K.N.; Berger, P.B.; Grill, D.E.; Bell, M.R.; Rihal, C.S.; Holmes, D.R., Jr. Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am. J. Med. 2000, 108, 187–192. [Google Scholar] [CrossRef]
  37. Steg, P.G.; Dabbous, O.H.; Feldman, L.J.; Cohen-Solal, A.; Aumont, M.C.; Lopez-Sendon, J.; Budaj, A.; Goldberg, R.J.; Klein, W.; Anderson, F.A., Jr.; et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004, 109, 494–499. [Google Scholar] [CrossRef]
  38. Sulo, G.; Igland, J.; Vollset, S.E.; Nygard, O.; Ebbing, M.; Sulo, E.; Egeland, G.M.; Tell, G.S. Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation-wide Analysis Including 86,771 Patients from the Cardiovascular Disease in Norway (CVDNOR) Project. J. Am. Heart Assoc. 2016, 5, e002667. [Google Scholar] [CrossRef]
  39. Lewis, E.F.; Velazquez, E.J.; Solomon, S.D.; Hellkamp, A.S.; McMurray, J.J.; Mathias, J.; Rouleau, J.L.; Maggioni, A.P.; Swedberg, K.; Kober, L.; et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: A VALIANT study. Eur. Heart J. 2008, 29, 748–756. [Google Scholar] [CrossRef]
  40. Wellings, J.; Kostis, J.B.; Sargsyan, D.; Cabrera, J.; Kostis, W.J.; Myocardial Infarction Data Acquisition System Study Group. Risk Factors and Trends in Incidence of Heart Failure Following Acute Myocardial Infarction. Am. J. Cardiol. 2018, 122, 1–5. [Google Scholar] [CrossRef]
  41. Regan, J.A.; Kitzman, D.W.; Leifer, E.S.; Kraus, W.E.; Fleg, J.L.; Forman, D.E.; Whellan, D.J.; Wojdyla, D.; Parikh, K.; O’Connor, C.M.; et al. Impact of Age on Comorbidities and Outcomes in Heart Failure with Reduced Ejection Fraction. JACC Heart Fail. 2019, 7, 1056–1065. [Google Scholar] [CrossRef]
  42. Agrinier, N.; Thilly, N.; Briancon, S.; Juilliere, Y.; Mertes, P.M.; Villemot, J.P.; Alla, F.; Zannad, F.; EPICAL group. Prognostic factors associated with 15-year mortality in patients with hospitalized systolic HF: Results of the observational community-based EPICAL cohort study. Int. J. Cardiol. 2017, 228, 940–947. [Google Scholar] [CrossRef] [PubMed]
  43. Tromp, J.; Shen, L.; Jhund, P.S.; Anand, I.S.; Carson, P.E.; Desai, A.S.; Granger, C.B.; Komajda, M.; McKelvie, R.S.; Pfeffer, M.A.; et al. Age-Related Characteristics and Outcomes of Patients with Heart Failure with Preserved Ejection Fraction. J. Am. Coll. Cardiol. 2019, 74, 601–612. [Google Scholar] [CrossRef] [PubMed]
  44. O’Connor, C.M.; Gattis, W.A.; Shaw, L.; Cuffe, M.S.; Califf, R.M. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am. J. Cardiol. 2000, 86, 863–867. [Google Scholar] [CrossRef] [PubMed]
  45. Kontogeorgos, S.; Thunstrom, E.; Johansson, M.C.; Fu, M. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Int. J. Cardiol. 2017, 232, 86–92. [Google Scholar] [CrossRef]
  46. Gottdiener, J.S.; McClelland, R.L.; Marshall, R.; Shemanski, L.; Furberg, C.D.; Kitzman, D.W.; Cushman, M.; Polak, J.; Gardin, J.M.; Gersh, B.J.; et al. Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study. Ann. Intern. Med. 2002, 137, 631–639. [Google Scholar] [CrossRef]
Jcm 14 00928 g001
Figure 1. Bar chart displaying the distribution of CAD severity across age groups in 10-year increments within the entire study cohort.
Figure 1. Bar chart displaying the distribution of CAD severity across age groups in 10-year increments within the entire study cohort.
Jcm 14 00928 g001
Jcm 14 00928 g002
Figure 2. Bar charts displaying the distribution of CAD severity across age groups in 10-year increments within subgroups of patients presenting with unstable angina (A), STEMI (B), NSTEMI (C), decompensated HF during index hospitalization (D), LVEF ≥ 35% (E), and LVEF < 35% (F). HF, heart failure; LVEF, left ventricular ejection fraction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Figure 2. Bar charts displaying the distribution of CAD severity across age groups in 10-year increments within subgroups of patients presenting with unstable angina (A), STEMI (B), NSTEMI (C), decompensated HF during index hospitalization (D), LVEF ≥ 35% (E), and LVEF < 35% (F). HF, heart failure; LVEF, left ventricular ejection fraction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Jcm 14 00928 g002
Jcm 14 00928 g003
Figure 3. Prognostic impact of age in unselected patients on the risk of HF-related rehospitalization at 36 months (A), coronary revascularization at 36 months (B), and AMI at 36 months (C). AMI, acute myocardial infarction; CI, confidence interval; HF, heart failure; HR, hazard ratio.
Figure 3. Prognostic impact of age in unselected patients on the risk of HF-related rehospitalization at 36 months (A), coronary revascularization at 36 months (B), and AMI at 36 months (C). AMI, acute myocardial infarction; CI, confidence interval; HF, heart failure; HR, hazard ratio.
Jcm 14 00928 g003
Jcm 14 00928 g004
Figure 4. Forest plot displaying multivariable Cox regression analyses with regard to the risk of HF-related rehospitalization at 36 months within the entire study cohort. AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Figure 4. Forest plot displaying multivariable Cox regression analyses with regard to the risk of HF-related rehospitalization at 36 months within the entire study cohort. AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Jcm 14 00928 g004
Jcm 14 00928 g005
Figure 5. Forest plot displaying subgroup analyses investigating the prognostic impact of age with regard to the risk of HF-related rehospitalization at 36 months. HF, heart failure; LVEF, left ventricular ejection fraction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Figure 5. Forest plot displaying subgroup analyses investigating the prognostic impact of age with regard to the risk of HF-related rehospitalization at 36 months. HF, heart failure; LVEF, left ventricular ejection fraction; (N)STEMI, (non-)ST segment elevation myocardial infarction.
Jcm 14 00928 g005
Table 1. Baseline characteristics.
Table 1. Baseline characteristics.
Age 40–<60 yrs
(n = 1901)		Age 60–<80 yrs
(n = 4064)		Age 80 yrs
(n = 1555)		p Value
Age, median (IQR)54(49–57)71(66–76)83(82–86)0.001
Male sex, n (%)1427(75.1)2574(63.3)868(55.8)0.001
Body mass index, kg/m2, median (IQR)28.1(25.1–32.1)27.5(24.5–31.1)26.0(23.6–29.3)0.001
Cardiovascular risk factors, n (%)
 Arterial hypertension1548(81.4)3534(87.0)1361(87.5)0.001
 Diabetes mellitus431(22.7)1346(33.1)508(32.7)0.001
 Hyperlipidemia839(44.1)1369(33.7)453(29.1)0.001
Prior medical history, n (%)
 Congestive heart failure86(4.5)381(9.4)203(13.1)0.001
 Pacemaker11(0.6)71(1.7)33(2.1)0.001
 COPD31(1.6)200(4.9)66(4.2)0.001
 Chronic kidney disease41(2.2)232(5.7)146(9.4)0.001
 Liver cirrhosis26(1.4)54(1.3)8(0.5)0.026
 Malignancy45(2.4)286(7.0)114(7.3)0.001
 Stroke5(0.3)31(0.8)23(1.5)0.001
Comorbidities at index hospitalization, n (%)
Acute coronary syndrome
 Unstable angina610(32.1)1037(25.5)340(21.9)0.001
 STEMI347(18.3)406(10.0)123(7.9)0.001
 NSTEMI321(16.9)723(17.8)326(21.0)0.005
Atrial fibrillation226(11.9)1142(28.1)635(40.8)0.001
Atrial flutter8(0.4)106(2.6)48(3.1)0.001
Acute decompensated heart failure92(4.8)496(12.2)330(21.2)0.001
Cardiogenic shock52(2.7)185(4.6)77(5.0)0.001
Atrioventricular block10(0.5)102(2.5)81(5.2)0.001
Cardiopulmonary resuscitation120(6.3)296(7.3)112(7.2)0.374
 Out-of-hospital93(4.9)201(4.9)74(4.8)0.959
 In-hospital27(1.4)95(2.3)38(2.4)0.046
Valvular heart disease116(6.1)683(16.8)488(31.4)0.001
Stroke57(3.0)168(4.1)61(3.9)0.098
LVEF, n (%)
 >55961(55.4)1715(47.7)579(41.5)0.001
 45–55%386(22.3)784(21.8)337(24.2)
 35–44%175(10.1)522(14.5)256(18.4)
 <35%212(12.2)576(16.0)223(16.0)
 Not documented167 467 160
COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; IQR, interquartile range; (N)STEMI, (non-)ST segment elevation myocardial infarction. Level of significance p ≤ 0.05. Bold type indicates statistical significance.
Table 2. Procedural, laboratory, and follow-up data.
Table 2. Procedural, laboratory, and follow-up data.
Age 40–<60 yrs
(n = 1901)		Age 60–<80 yrs
(n = 4064)		Age ≥ 80 yrs
(n = 1555)		p Value
Coronary angiography, n (%)
 No evidence of coronary artery disease725(38.1)1145(28.2)353(22.7)0.001
 1-vessel disease414(21.8)792(19.5)293(18.8)
 2-vessel disease363(19.1)848(20.9)348(22.4)
 3-vessel disease399(21.0)1279(31.5)561(36.1)
 Right coronary artery754(39.7)2000(49.2)806(51.8)0.001
 Left main trunc113(5.9)487(12.0)243(15.6)0.001
 Left anterior descending865(45.5)2285(56.2)990(63.7)0.001
 Left circumflex636(33.5)1794(44.1)755(48.6)0.001
 Ramus intermedius153(8.0)485(11.9)207(13.3)0.001
 CABG22(1.2)132(3.2)73(4.7)0.001
 Chronic total occlusion119(6.3)374(9.2)121(7.8)0.001
PCI, n (%)830(43.7)1753(43.1)679(43.7)0.908
 Right coronary artery345(18.1)681(16.7)243(15.6)0.136
 Left main trunc47(2.5)149(3.7)95(6.1)0.001
 Left anterior descending421(22.1)900(22.1)377(24.2)0.201
 Left circumflex265(13.9)586(14.4)228(14.7)0.819
 Ramus intermedius41(2.2)71(1.7)24(1.5)0.368
 CABG3(0.2)37(0.9)15(1.0)0.003
Sent to CABG, n (%)76(4.0)223(5.5)39(2.5)0.001
Procedural data
 Number of stents, median (IQR)2(1–3)2(1–3)2(1–3)0.599
 Stent length, median (IQR)44(24–76)44(24–76)44(24–76)0.648
 Contrast, median (IQR)109(69–184)116(70–200)121(75–202)0.003
Baseline laboratory values, median (IQR)
 Sodium, mmol/L139(138–141)139(138–141)140(138–141)0.403
 Potassium, mmol/L3.92(3.72–4.15)3.96(3.73–4.22)3.95(3.72–4.25)0.001
 Calcium, mmol/L2.22(2.14–2.31)2.21(2.13–2.30)2.20(2.11–2.29)0.001
 Creatinine, mg/dL0.93(0.80–1.08)1.05(0.87–1.36)1.19(0.94–1.64)0.001
 eGFR, mL/min/1.73 m281.5(70.2–94.9)66.3(50.2–81.3)53.0(39.4–68.4)0.001
 Urea, mg/dL31.2(25.8–38.6)39.4(30.9–54.1)48.9(36.2–69.3)0.001
 Hemoglobin, g/dL14.2(12.9–15.2)13.1(11.5–14.3)12.2(10.7–13.4)0.001
 WBC count, × 109/L9.3(7.4–11.6)8.8(7.1–11.2)8.7(6.9–11.1)0.001
 Platelet count, × 109/L245(204–292)234(191–284)220(179–267)0.001
 HbA1c, %5.7(5.4–6.3)5.9(5.5–6.8)5.9(5.5–6.7)0.001
 LDL-cholesterol, mg/dL 122(95–148)100(77–131)90(68–120)0.001
 HDL-cholesterol, mg/dL40(33–49)43(35–54)46(37–56)0.001
 Triglycerides, mg/dL143(102–208)126(94–173)148(111–197)0.001
 C-reactive protein, mg/L16.6(7.1–55.2)28.6(9.0–87.0)36.2(12.0–94.6)0.001
 Procalcitonin, µg/L0.30(0.09–1.34)0.43(0.15–1.93)0.30(0.11–1.19)0.001
 Albumin, g/L35.8(33.0–38.5)34.1(30.2–37.0)32.5(29.1–35.5)0.001
 INR1.03(0.99–1.09)1.06(1.01–1.15)1.09(1.02–1.21)0.001
 NT-pro BNP, pg/mL699(156–2359)2188(577–6075)3859(1580–9633)0.001
 Cardiac troponin I, µg/L1.48(0.16–12.02)0.59(0.10–4.51)0.54(0.09–3.04)0.001
 Creatine kinase, U/L162(96–396)126(78–271)121(75–245)0.001
 Creatine kinase MB, U/L35(22–80)31(21–64)30(20–53)0.001
Medication at discharge, n (%)
 ACE inhibitor980(53.6)1900(50.3)691(49.2)0.024
 ARB311(17.0)977(25.9)416(29.6)0.001
 Beta-blocker1203(65.8)2736(72.4)1047(74.6)0.001
 Aldosterone antagonist230(12.6)590(15.6)228(16.2)0.004
 ARNI27(1.5)39(1.0)10(0.7)0.104
 SGLT2 inhibitor96(5.3)200(5.3)45(3.2)0.005
 Statin1271(69.5)2902(76.8)1058(75.4)0.001
 ASA1234(67.5)2486(65.8)854(60.8)0.001
 P2Y12 inhibitor862(47.2)1807(47.8)687(48.9)0.604
 OAC210(11.5)1162(30.8)611(43.5)0.001
Follow-up data, median (IQR)
 Hospitalization time6(4–9)7(5–13).9(5–15)0.001
 ICU time0(0–0)0(0–0)0(0–0)0.127
All-cause mortality, in hospital, n (%)73(3.8)288(7.1)151(9.7)0.001
Patients discharged alive, n (%)1828(96.2)3776(92.9)1404(90.3)
Primary endpoint, n (%)
 HF-related rehospitalization, at 36 months256(14.0)876(23.2)399(28.4)0.001
Secondary endpoints, n (%)
 Coronary revascularization, at 36 months148(8.1)340(9.0)101(7.2)0.098
 Acute myocardial infarction, at 36 months135(7.4)297(7.9)101(7.2)0.663
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; DOAC, directly acting oral anticoagulant; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; ICU, intensive care unit; IQR, interquartile range; LDL, low-density lipoprotein; NT-pro BNP, aminoterminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; SGLT2, sodium glucose linked transporter 2; WBC, white blood cell. Level of significance: p ≤ 0.05. Bold type indicates statistical significance.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kuhn, L.; Schupp, T.; Steinke, P.; Dudda, J.; Abumayyaleh, M.; Weidner, K.; Bertsch, T.; Rusnak, J.; Akin, I.; Behnes, M. Age-Related Outcomes in Patients Undergoing Coronary Angiography: In Which Subgroups Does Age Matter? Results from a Large-Scale Retrospective Registry. J. Clin. Med. 2025, 14, 928. https://doi.org/10.3390/jcm14030928

AMA Style

Kuhn L, Schupp T, Steinke P, Dudda J, Abumayyaleh M, Weidner K, Bertsch T, Rusnak J, Akin I, Behnes M. Age-Related Outcomes in Patients Undergoing Coronary Angiography: In Which Subgroups Does Age Matter? Results from a Large-Scale Retrospective Registry. Journal of Clinical Medicine. 2025; 14(3):928. https://doi.org/10.3390/jcm14030928

Chicago/Turabian Style

Kuhn, Lasse, Tobias Schupp, Philipp Steinke, Jonas Dudda, Mohammad Abumayyaleh, Kathrin Weidner, Thomas Bertsch, Jonas Rusnak, Ibrahim Akin, and Michael Behnes. 2025. "Age-Related Outcomes in Patients Undergoing Coronary Angiography: In Which Subgroups Does Age Matter? Results from a Large-Scale Retrospective Registry" Journal of Clinical Medicine 14, no. 3: 928. https://doi.org/10.3390/jcm14030928

APA Style

Kuhn, L., Schupp, T., Steinke, P., Dudda, J., Abumayyaleh, M., Weidner, K., Bertsch, T., Rusnak, J., Akin, I., & Behnes, M. (2025). Age-Related Outcomes in Patients Undergoing Coronary Angiography: In Which Subgroups Does Age Matter? Results from a Large-Scale Retrospective Registry. Journal of Clinical Medicine, 14(3), 928. https://doi.org/10.3390/jcm14030928

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop